These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
60 related articles for article (PubMed ID: 2226235)
1. Efficacy of Kemron (low dose oral natural human interferon alpha) in the management of HIV-1 infection and acquired immune deficiency syndrome (AIDS). Koech DK; Obel AO East Afr Med J; 1990 Jul; 67(7 Suppl 2):SS64-70. PubMed ID: 2226235 [TBL] [Abstract][Full Text] [Related]
2. Low dose oral alpha-interferon therapy for patients seropositive for human immunodeficiency virus type-1 (HIV-1). Koech DK; Obel AO; Minowada J; Hutchinson VA; Cummins JM Mol Biother; 1990 Jun; 2(2):91-5. PubMed ID: 1973045 [TBL] [Abstract][Full Text] [Related]
3. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204 [TBL] [Abstract][Full Text] [Related]
4. Outcome of intervention with or without low dose oral interferon alpha in thirty-two HIV-1 seropositive patients in a referral hospital. Obel AO; Koech DK East Afr Med J; 1990 Jul; 67(7 Suppl 2):SS71-6. PubMed ID: 1977577 [TBL] [Abstract][Full Text] [Related]
5. Kemron. Low dose natural human interferon alpha for oral administration (general information and technical details). East Afr Med J; 1990 Jul; 67(7 Suppl 2):SS82-6. PubMed ID: 2226237 [No Abstract] [Full Text] [Related]
6. An interim report on the effect of natural human interferon alpha (IFN-alpha) lozenges in patients seropositive for the human immunodeficiency virus type 1 (HIV-1). Babiuch L; Mian M; Kamińska E; Szymańska B; Georgiades JA Arch Immunol Ther Exp (Warsz); 1993; 41(3-4):213-9. PubMed ID: 7907465 [TBL] [Abstract][Full Text] [Related]
7. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B; Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960 [TBL] [Abstract][Full Text] [Related]
8. Recommended dose for repair of serum vitamin A levels in patients with HIV infection/AIDS may be insufficient because of high urinary losses. Neves FF; Vannucchi H; Jordão AA; Figueiredo JF Nutrition; 2006 May; 22(5):483-9. PubMed ID: 16472980 [TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy and alpha-interferon in the treatment of Kaposi's sarcoma associated with acquired immune deficiency syndrome. Shepherd FA; Evans WK; Garvey B; Read SE; Klein M; Fanning MM; Coates R CMAJ; 1988 Oct; 139(7):635-9. PubMed ID: 2458177 [TBL] [Abstract][Full Text] [Related]
10. Treatment of recurrent common warts with one low dose of intralesional natural human leukocyte interferon alpha. Pueyo S; Criscuolo M; Davidovich C; Zorzópulos J; Pesce A; Díaz A J Biol Regul Homeost Agents; 1990; 4(2):47-50. PubMed ID: 2260502 [TBL] [Abstract][Full Text] [Related]
11. Global update: Kenya. AIDSlink; 1993; (23):14. PubMed ID: 12159243 [TBL] [Abstract][Full Text] [Related]
12. High-energy, high-protein, oral, liquid, nutrition supplementation in patients with HIV infection: effect on weight status in relation to incidence of secondary infection. Stack JA; Bell SJ; Burke PA; Forse RA J Am Diet Assoc; 1996 Apr; 96(4):337-41. PubMed ID: 8598433 [TBL] [Abstract][Full Text] [Related]
13. [Human immunodeficiency virus infections (HIV-1 and HIV-2) in Dakar. Epidemiologic and clinical aspects]. Barabe P; Digoutte JP; Tristan JF; Peghini M; Griffet P; Jean P; Seignot P; Sarthou JL; Leguenno B; Berlioz C Med Trop (Mars); 1988; 48(4):337-44. PubMed ID: 3221781 [TBL] [Abstract][Full Text] [Related]
14. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B. Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911 [TBL] [Abstract][Full Text] [Related]
15. Tolerability and activity of a new recombinant interferon-alpha B/D hybrid in patients with HIV-1 infection. Frissen PH; Brinkman K; Ten Napel CH; van der Ende IM; van Buuren IA; Boucher CA; Reiss P; Lange JM Antivir Ther; 1996 Apr; 1(2):89-97. PubMed ID: 11321184 [TBL] [Abstract][Full Text] [Related]
16. Clinico-epidemiological patterns of HIV infection in STD patients in Ibadan. Ekweozor CC; Olaleye OD; Tomori O; Saliu I; Essien EM; Bakare RA; Oni AA; Oyewo OO; Okesola AO; Onyemenem TN Afr J Med Med Sci; 1995 Dec; 24(4):321-7. PubMed ID: 8886145 [TBL] [Abstract][Full Text] [Related]
17. Ocular manifestations of HIV infection. Jabs DA Trans Am Ophthalmol Soc; 1995; 93():623-83. PubMed ID: 8719695 [TBL] [Abstract][Full Text] [Related]
18. Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. Kamga I; Kahi S; Develioglu L; Lichtner M; Marañón C; Deveau C; Meyer L; Goujard C; Lebon P; Sinet M; Hosmalin A J Infect Dis; 2005 Jul; 192(2):303-10. PubMed ID: 15962225 [TBL] [Abstract][Full Text] [Related]
19. Outcomes of human immunodeficiency virus-infected and -exposed children undergoing surgery--a prospective study. Karpelowsky JS; Leva E; Kelley B; Numanoglu A; Rode H; Millar AJ J Pediatr Surg; 2009 Apr; 44(4):681-7. PubMed ID: 19361626 [TBL] [Abstract][Full Text] [Related]
20. Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells. Lapenta C; Santini SM; Proietti E; Rizza P; Logozzi M; Spada M; Parlato S; Fais S; Pitha PM; Belardelli F Virology; 1999 Oct; 263(1):78-88. PubMed ID: 10544084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]